Investor Presentaiton

Execution of Play To Win strategy in Vaccines sanofi Focus on growth Lead with innovation +8% Sales growth 32 2018-2022 CAGR Countries with Beyfortus licenses Vaccines profitability +6pts from 2018 to 2022 2 Vaccines reached blockbuster status - - Fluzone HD Penta/Hexaxim New phase 1/2 programs over 2022-2023 1 Accelerate efficiency Merged Pharma & Vaccines manufacturing & supply, 2 Evolutive Facilities on track for 2025 operation Reinvent how we work +90% TBio experts retained across mRNA Center of Excellence 2 years post-acquisition 45% Female senior leaders 12 Vaccines Investor Event

View entire presentation